10-Q
--03-310001804591Q22024falsethree year0001804591us-gaap:CommonClassAMember2022-04-012022-09-300001804591me:PgsMember2023-04-012023-09-300001804591us-gaap:AccountsReceivableMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591srt:MaximumMemberme:AAndRPlanMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-06-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:CommonClassAMember2023-10-310001804591me:GSKMember2022-04-012022-09-300001804591srt:MinimumMember2023-04-012023-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2022-07-012022-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2022-04-012022-09-300001804591me:PartnershipsMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591me:DevelopedTechnologyMember2023-03-310001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMember2023-04-012023-09-300001804591me:AipMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001804591country:US2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:CommonClassBMember2023-10-310001804591us-gaap:HealthCareOtherMember2023-04-012023-09-300001804591me:OtherRegionsMember2022-04-012022-09-300001804591us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001804591us-gaap:LeaseholdImprovementsMember2023-03-310001804591us-gaap:CommonClassAMember2023-04-012023-09-300001804591me:DeferredRevenueMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-03-310001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001804591us-gaap:CommonClassBMember2023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:PgsMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:CommonStockMember2023-04-012023-06-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-3000018045912021-04-012022-03-310001804591srt:MaximumMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2022-04-012022-09-300001804591us-gaap:CorporateMember2022-07-012022-09-300001804591us-gaap:ServiceMember2022-07-012022-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001804591me:IncentiveEquityPlanMemberus-gaap:CommonClassAMember2021-06-100001804591us-gaap:AdditionalPaidInCapitalMember2023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:CommonClassBMember2022-07-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2023-04-012023-09-300001804591me:IncentiveEquityPlanMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2023-09-300001804591me:ConsumerAndResearchServicesMember2022-04-012022-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:MicroarraysMember2023-04-012023-09-300001804591me:GSKMember2023-04-012023-09-300001804591me:InternalUseSoftwareMember2023-04-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591me:ConsumerAndResearchServicesMember2023-07-012023-09-300001804591us-gaap:CommonClassBMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-03-310001804591me:AipMember2023-09-300001804591me:InternalUseSoftwareMember2022-04-012022-09-300001804591me:PIPEInvestorsMember2021-04-012022-03-310001804591me:ComputerAndSoftwareMember2023-03-310001804591me:CustomerFMember2022-04-012023-03-310001804591us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001804591us-gaap:RetainedEarningsMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2023-07-012023-09-3000018045912023-06-300001804591me:ConsumerServicesMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-09-300001804591country:US2023-04-012023-09-300001804591me:GSKMember2022-04-012023-03-310001804591me:EmployeeStockPurchasePlanMember2021-06-102021-06-100001804591me:CapitalizedAssetRetirementObligationsMember2023-03-310001804591us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:OtherRegionsMember2023-07-012023-09-300001804591us-gaap:CorporateMember2023-07-012023-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:TherapeuticsMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:CustomersRelationshipsMember2023-03-310001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:ComputerAndSoftwareMember2023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMember2023-03-310001804591me:ConsumerServicesMember2022-04-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:IncentiveEquityPlanMemberus-gaap:EmployeeStockOptionMember2023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2022-07-012022-09-3000018045912022-06-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001804591us-gaap:OtherRestructuringMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2022-07-012022-09-300001804591me:ConsumerAndResearchServicesMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2022-04-012022-09-300001804591me:ResearchServicesMember2022-07-012022-09-300001804591me:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-04-012023-09-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:VGAcquisitionSponsorLLCMember2023-04-012023-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMember2023-07-012023-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591me:GSKMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2022-07-012022-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001804591us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:AipMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:EmployeeStockOptionMember2023-07-012023-09-3000018045912023-04-012023-09-300001804591me:ConsumerServicesMember2023-09-300001804591us-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:CommonClassBMember2023-07-012023-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMember2022-07-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591srt:MaximumMember2023-07-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2022-07-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:ResearchServicesMember2023-04-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2022-04-012023-03-310001804591us-gaap:NoncompeteAgreementsMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:ConsumerServicesMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CommonClassAMember2023-09-300001804591me:IncentiveEquityPlanMembersrt:MinimumMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:AAndRPlanMemberus-gaap:CommonClassAMemberme:LemonaidHealthIncMember2023-09-300001804591me:VGAcquisitionSponsorLLCMember2022-04-012023-03-310001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591me:LaboratoryEquipmentAndSoftwareMember2023-09-300001804591me:AipMember2022-07-012022-09-300001804591us-gaap:RetainedEarningsMember2022-04-012022-06-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-04-012023-09-300001804591country:GB2022-07-012022-09-300001804591me:ConsumerAndResearchServicesMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2022-04-012022-09-300001804591me:ConsumerServicesMember2022-07-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2022-04-012022-09-300001804591me:AipMember2023-03-310001804591srt:MaximumMemberme:AAndRPlanMemberus-gaap:CommonClassAMemberme:NonEmployeeDirectorsMemberme:LemonaidHealthIncMember2023-09-300001804591us-gaap:RetainedEarningsMember2022-07-012022-09-300001804591me:RelinquishmentTriggeringEventMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-11-012023-11-010001804591me:GSKMember2023-03-310001804591us-gaap:SubsequentEventMemberme:AmendmentToGskAgreementMember2023-10-270001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2023-04-012023-09-300001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-03-310001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:OtherRegionsMember2023-07-012023-09-300001804591me:PgsMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591srt:MaximumMemberme:AAndRPlanMemberus-gaap:CommonClassAMember2023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CorporateMember2022-04-012022-09-300001804591us-gaap:CommonStockMember2022-07-012022-09-300001804591me:CowenAndCompanyLlcMembersrt:MaximumMemberme:SalesAgreementMember2023-02-060001804591country:CA2022-07-012022-09-3000018045912022-04-012022-06-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:PatentsMember2023-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591me:InternalUseSoftwareMember2022-07-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2023-07-012023-09-3000018045912022-03-310001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:CommonClassAMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-07-012023-09-300001804591srt:MinimumMember2022-07-012022-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:PatentsMember2023-03-310001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591country:CA2022-04-012022-09-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-300001804591me:AipMember2022-04-012022-09-300001804591us-gaap:CommonStockMember2023-06-3000018045912023-02-062023-02-060001804591us-gaap:RetainedEarningsMember2023-06-300001804591me:VariableInterestEntitiesMember2022-07-012022-09-300001804591me:TherapeuticsMember2022-04-012022-09-300001804591me:TrademarkMember2023-03-310001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2023-07-012023-09-300001804591country:GB2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2023-04-012023-09-300001804591me:LemonaidHealthLimitedMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:CorporateMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2022-04-012022-09-300001804591us-gaap:ServiceMember2022-04-012022-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-03-310001804591us-gaap:CommonStockMember2023-07-012023-09-300001804591me:CustomerFMember2023-04-012023-09-300001804591country:CA2023-04-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001804591me:PartnershipsMember2023-09-300001804591me:DevelopedTechnologyMember2023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-03-310001804591srt:MaximumMember2023-04-012023-09-300001804591country:US2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2023-04-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-09-300001804591us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:NoncompeteAgreementsMember2023-03-310001804591country:CA2023-07-012023-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2022-04-012022-09-300001804591us-gaap:CommonClassAMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001804591us-gaap:EmployeeStockOptionMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300001804591me:OtherRegionsMember2023-04-012023-09-300001804591us-gaap:RetainedEarningsMember2022-06-300001804591srt:MinimumMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-06-3000018045912022-04-012023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2023-07-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-07-012023-09-300001804591us-gaap:CommonStockMember2023-03-310001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-3000018045912023-03-310001804591me:FurnitureAndOfficeEquipmentMember2023-03-310001804591me:CustomersRelationshipsMember2023-09-300001804591me:ResearchServicesMember2023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:AccountsPayableMember2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMember2023-09-300001804591us-gaap:CommonClassBMember2022-04-012022-09-300001804591country:GB2023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2022-07-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMemberme:CustomerBMember2022-04-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:CustomerCMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2022-04-012022-09-300001804591me:CustomerCMemberus-gaap:SalesRevenueNetMemberme:ConsumerAndResearchServicesMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001804591us-gaap:CommonStockMember2023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MaximumMember2023-04-012023-09-300001804591us-gaap:LeaseholdImprovementsMember2023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:GSKMember2022-10-312022-10-310001804591me:CustomerCMember2022-04-012023-03-310001804591us-gaap:FairValueMeasurementsNonrecurringMember2023-07-012023-09-300001804591me:ResearchServicesMember2023-07-012023-09-300001804591country:GB2023-04-012023-09-300001804591me:ResearchServicesMember2023-03-310001804591me:LaboratoryEquipmentAndSoftwareMember2023-03-310001804591us-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:RetainedEarningsMember2023-04-012023-06-300001804591srt:MinimumMember2022-04-012022-09-300001804591us-gaap:HealthCareOtherMember2022-04-012022-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591country:US2022-04-012022-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2022-04-012022-09-300001804591me:GSKMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2022-04-012022-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591me:InternalUseSoftwareMember2023-07-012023-09-300001804591me:OtherRegionsMember2022-07-012022-09-300001804591me:TrademarkMember2023-09-300001804591us-gaap:CommonClassAMember2022-07-012022-09-300001804591me:ConsumerServicesMember2023-03-3100018045912022-04-012022-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000018045912022-09-300001804591me:GSKMember2022-07-012022-09-300001804591me:CustomerCMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2022-07-012022-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2022-04-012022-09-300001804591me:TwoThousandAndSixEquityIncentivePlanMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2023-07-012023-09-300001804591srt:MinimumMemberme:AAndRPlanMemberme:LemonaidHealthIncMember2023-04-012023-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:FormerLemonaidOfficerMember2023-04-012023-09-300001804591us-gaap:CommonStockMember2022-04-012022-06-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:EmployeeStockPurchasePlanMembersrt:MinimumMember2022-04-012022-09-300001804591me:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591srt:MinimumMemberme:AAndRPlanMemberus-gaap:CommonClassAMember2023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2021-06-100001804591me:IncentiveEquityPlanMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001804591us-gaap:AccountsPayableMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:ResearchServicesMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMember2023-04-012023-09-300001804591us-gaap:CommonClassAMember2023-03-310001804591us-gaap:AdditionalPaidInCapitalMember2023-03-310001804591srt:MaximumMember2022-07-012022-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:DeferredRevenueMember2023-04-012023-09-300001804591me:AipMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591me:LemonaidHealthIncMember2021-11-012021-11-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:VariableInterestEntitiesMember2023-07-012023-09-300001804591me:VGAcquisitionSponsorLLCMembersrt:MinimumMemberus-gaap:CommonClassAMember2023-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:KITSMember2022-04-012022-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:CommonClassBMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2022-06-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:AccountsReceivableMember2022-04-012022-09-300001804591us-gaap:FairValueMeasurementsNonrecurringMember2023-04-012023-09-300001804591srt:MinimumMember2023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2023-04-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2022-07-012022-09-300001804591us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001804591me:VGAcquisitionSponsorLLCMembersrt:MaximumMember2023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-04-012022-09-300001804591me:CapitalizedAssetRetirementObligationsMember2023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591srt:MinimumMemberme:AAndRPlanMemberus-gaap:CommonClassAMemberme:NonEmployeeDirectorsMemberme:LemonaidHealthIncMember2023-09-300001804591me:EmployeeStockPurchasePlanMember2021-06-100001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:CA2022-07-012022-09-3000018045912023-04-012023-06-300001804591me:PgsMember2022-04-012022-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2022-07-012022-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-07-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-09-300001804591me:FurnitureAndOfficeEquipmentMember2023-09-300001804591me:ResearchServicesMember2022-04-012022-09-3000018045912023-07-012023-09-300001804591me:ResearchServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:GB2022-07-012022-09-300001804591us-gaap:HealthCareOtherMemberus-gaap:TransferredAtPointInTimeMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:HealthCareOtherMemberus-gaap:TransferredOverTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591us-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:SalesRevenueNetMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-09-300001804591me:TherapeuticsMember2023-04-012023-09-3000018045912022-07-012022-09-300001804591me:LemonaidHealthLimitedMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:LemonaidHealthIncMember2022-04-012022-09-300001804591srt:MaximumMember2022-04-012022-09-300001804591us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberme:LaboratoryServicesMember2022-07-012022-09-300001804591us-gaap:SalesRevenueNetMemberme:ConsumerServicesMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300001804591me:PgsMember2022-07-012022-09-3000018045912023-09-300001804591us-gaap:FairValueMeasurementsRecurringMember2023-03-310001804591us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-09-300001804591us-gaap:SalesRevenueNetMemberme:PgsMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMember2022-04-012022-09-300001804591me:TherapeuticsMember2022-07-012022-09-300001804591us-gaap:OtherRestructuringMember2023-07-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-30xbrli:purexbrli:sharesme:Voteiso4217:USD
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO___________
Commission File Number 001-39587
23ANDME HOLDING CO.
(Exact name of Registrant as specified in its Charter)
|
|
Delaware |
87-1240344 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
349 Oyster Point Boulevard South San Francisco, California |
94080 |
(Address of principal executive offices) |
(Zip Code) |
(650) 938-6300
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Class A common stock, $0.0001 par value per share |
ME |
The Nasdaq Global Select Market |
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 31, 2023, there were 311,613,095 shares of Class A common stock, $0.0001 par value per share, and 167,491,460 shares of Class B common stock, $0.0001 par value per share, issued and outstanding.
Table of Contents
23ANDME HOLDING CO.
TABLE OF CONTENTS
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Form 10-Q”), including, without limitation, statements under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Generally, statements that are not historical facts, including statements concerning 23andMe Holding Co.’s (the “Company,” “23andMe,” “we,” “us,” or “our”) possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, words like “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations.
The forward-looking statements contained in this Form 10-Q are based on our current expectations and beliefs, which we believe to be reasonable, concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, without limitation, those factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on May 25, 2023, and our subsequent reports filed with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition, and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.
3
Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
23ANDME HOLDING CO.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
March 31, |
|
|
|
2023 |
|
|
2023 |
|
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
256,386 |
|
|
$ |
386,849 |
|
Restricted cash |
|
|
1,399 |
|
|
|
1,399 |
|
Accounts receivable, net |
|
|
1,501 |
|
|
|
1,897 |
|
Inventories |
|
|
14,979 |
|
|
|
10,247 |
|
Deferred cost of revenue |
|
|
5,782 |
|
|
|
5,376 |
|
Prepaid expenses and other current assets |
|
|
17,948 |
|
|
|
19,224 |
|
Total current assets |
|
|
297,995 |
|
|
|
424,992 |
|
Property and equipment, net |
|
|
32,805 |
|
|
|
38,608 |
|
Operating lease right-of-use assets |
|
|
52,549 |
|
|
|
56,078 |
|
Restricted cash, noncurrent |
|
|
6,974 |
|
|
|
6,974 |
|
Internal-use software, net |
|
|
18,971 |
|
|
|
15,661 |
|
Intangible assets, net |
|
|
37,835 |
|
|
|
45,520 |
|
Goodwill |
|
|
351,744 |
|
|
|
351,744 |
|
Other assets |
|
|
2,357 |
|
|
|
3,021 |
|
Total assets |
|
$ |
801,230 |
|
|
$ |
942,598 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable (includes related party amounts of nil and $3,186, respectively) |
|
$ |
8,546 |
|
|
$ |
12,924 |
|
Accrued expenses and other current liabilities (includes related party amounts of $13,732 and $8,738, respectively) |
|
|
44,686 |
|
|
|
66,430 |
|
Deferred revenue (includes related party amounts of nil and $11,753, respectively) |
|
|
40,283 |
|
|
|
62,521 |
|
Operating lease liabilities |
|
|
8,086 |
|
|
|
7,541 |
|
Total current liabilities |
|
|
101,601 |
|
|
|
149,416 |
|
Operating lease liabilities, noncurrent |
|
|
72,963 |
|
|
|
77,763 |
|
Other liabilities |
|
|
1,415 |
|
|
|
1,480 |
|
Total liabilities |
|
|
175,979 |
|
|
|
228,659 |
|
Commitments and contingencies (Note 11) |
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
Preferred stock - par value $0.0001, 10,000,000 shares authorized as of September 30, 2023 and March 31, 2023; zero shares issued and outstanding as of September 30, 2023 and March 31, 2023 |
|
|
— |
|
|
|
— |
|
Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 311,339,539 and 293,020,474 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively; Class B shares, 350,000,000 shares authorized, 167,491,460 and 168,179,488 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively |
|
|
48 |
|
|
|
46 |
|
Additional paid-in capital |
|
|
2,311,481 |
|
|
|
2,220,897 |
|
Accumulated other comprehensive loss |
|
|
— |
|
|
|
(620 |
) |
Accumulated deficit |
|
|
(1,686,278 |
) |
|
|
(1,506,384 |
) |
Total stockholders’ equity |
|
|
625,251 |
|
|
|
713,939 |
|
Total liabilities and stockholders’ equity |
|
$ |
801,230 |
|
|
$ |
942,598 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Table of Contents
23ANDME HOLDING CO.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Six Months Ended September 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Revenue (includes related party revenue of $1,082 and $14,925 for the three months ended September 30, 2023 and 2022, respectively, and $11,753 and $23,190 for the six months ended September 30, 2023 and 2022, respectively) |
|
$ |
49,999 |
|
|
$ |
75,659 |
|
|
$ |
110,863 |
|
|
$ |
140,172 |
|
Cost of revenue (includes related party cost of $20 and $(271) for the three months ended September 30, 2023 and 2022, respectively, and $295 and $(510) for the six months ended September 30, 2023 and 2022, respectively) |
|
|
28,270 |
|
|
|
37,386 |
|
|
|
58,453 |
|
|
|
76,409 |
|
Gross profit |
|
|
21,729 |
|
|
|
38,273 |
|
|
|
52,410 |
|
|
|
63,763 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development (includes related party expenses of $4,907 and $2,717 for the three months ended September 30, 2023 and 2022, respectively, and $8,208 and $6,266 for the six months ended September 30, 2023 and 2022, respectively) |
|
|
54,588 |
|
|
|
52,598 |
|
|
|
116,917 |
|
|
|
104,607 |
|
Sales and marketing |
|
|
18,328 |
|
|
|
24,835 |
|
|
|
40,986 |
|
|
|
58,269 |
|
General and administrative |
|
|
25,290 |
|
|
|
28,881 |
|
|
|
76,030 |
|
|
|
58,524 |
|
Restructuring and other charges |
|
|
2,654 |
|
|
|
— |
|
|
|
6,871 |
|
|
|
— |
|
Total operating expenses |
|
|
100,860 |
|
|
|
106,314 |
|
|
|
240,804 |
|
|
|
221,400 |
|
Loss from operations |
|
|
(79,131 |
) |
|
|
(68,041 |
) |
|
|
(188,394 |
) |
|
|
(157,637 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
|
3,752 |
|
|
|
1,392 |
|
|
|
8,059 |
|
|
|
1,637 |
|
Other income (expense), net |
|
|
145 |
|
|
|
(687 |
) |
|
|
477 |
|
|
|
(1,122 |
) |
Loss before income taxes |
|
|
(75,234 |
) |
|
|
(67,336 |
) |
|
|
(179,858 |
) |
|
|
(157,122 |
) |
Provision for (benefit from) income taxes |
|
|
36 |
|
|
|
(1,271 |
) |
|
|
36 |
|
|
|
(1,525 |
) |
Net loss |
|
|
(75,270 |
) |
|
|
(66,065 |
) |
|
|
(179,894 |
) |
|
|
(155,597 |
) |
Other comprehensive income, net of tax |
|
|
954 |
|
|
|
829 |
|
|
|
620 |
|
|
|
1,453 |
|
Total comprehensive loss |
|
$ |
(74,316 |
) |
|
$ |
(65,236 |
) |
|
$ |
(179,274 |
) |
|
$ |
(154,144 |
) |
Net loss per share of Class A and Class B common stock attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.16 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.35 |
) |
Weighted-average shares used to compute net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
474,858,266 |
|
|
|
449,899,537 |
|
|
|
468,592,009 |
|
|
|
448,211,708 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Table of Contents
23ANDME HOLDING CO.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Total Stockholders’ Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Income (Loss) |
|
|
Deficit |
|
|
(Deficit) |
|
Balance as of March 31, 2023 |
|
|
461,199,962 |
|
|
$ |
46 |
|
|
$ |
2,220,897 |
|
|
$ |
(620 |
) |
|
$ |
(1,506,384 |
) |
|
$ |
713,939 |
|
Issuance of common stock upon exercise of stock options |
|
|
180,718 |
|
|
|
— |
|
|
|
85 |
|
|
|
— |
|
|
|
— |
|
|
|
85 |
|
Issuance of common stock upon release of restricted stock units |
|
|
1,812,802 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan |
|
|
8,961,053 |
|
|
|
1 |
|
|
|
18,629 |
|
|
|
— |
|
|
|
— |
|
|
|
18,630 |
|
Net share settlements for stock-based minimum tax withholdings |
|
|
(58,985 |
) |
|
|
— |
|
|
|
(121 |
) |
|
|
— |
|
|
|
— |
|
|
|
(121 |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
47,915 |
|
|
|
— |
|
|
|
— |
|
|
|
47,915 |
|
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(334 |
) |
|
|
— |
|
|
|
(334 |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(104,624 |
) |
|
|
(104,624 |
) |
Balance as of June 30, 2023 |
|
|
472,095,550 |
|
|
$ |
47 |
|
|
$ |
2,287,405 |
|
|
$ |
(954 |
) |
|
$ |
(1,611,008 |
) |
|
$ |
675,490 |
|
Issuance of common stock upon exercise of stock options |
|
|
828,561 |
|
|
|
— |
|
|
|
388 |
|
|
|
— |
|
|
|
— |
|
|
|
388 |
|
Issuance of common stock upon release of restricted stock units |
|
|
4,358,378 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Issuance of common stock upon release of restricted stock units under the 2022 Annual Incentive Plan |
|
|
57,996 |
|
|
|
— |
|
|
|
102 |
|
|
|
— |
|
|
|
— |
|
|
|
102 |
|
Net share settlements for stock-based minimum tax withholdings |
|
|
(19,022 |
) |
|
|
— |
|
|
|
(22 |
) |
|
|
— |
|
|
|
— |
|
|
|
(22 |
) |
Issuance of common stock under employee stock purchase plan |
|
|
1,509,536 |
|
|
|
— |
|
|
|
1,411 |
|
|
|
— |
|
|
|
— |
|
|
|
1,411 |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
22,198 |
|
|
|
— |
|
|
|
— |
|
|
|
22,198 |
|
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
954 |
|
|
|
— |
|
|
|
954 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(75,270 |
) |
|
|
(75,270 |
) |
Balance as of September 30, 2023 |
|
|
478,830,999 |
|
|
$ |
48 |
|
|
$ |
2,311,481 |
|
|
$ |
— |
|
|
$ |
(1,686,278 |
) |
|
$ |
625,251 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Total Stockholders’ Equity |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Income (Loss) |
|
|
Deficit |
|
|
(Deficit) |
|
Balance as of March 31, 2022 |
|
|
448,812,321 |
|
|
$ |
45 |
|
|
$ |
2,110,160 |
|
|
$ |
179 |
|
|
$ |
(1,194,728 |
) |
|
$ |
915,656 |
|
Issuance of common stock upon exercise of stock options |
|
|
1,065,784 |
|
|
|
— |
|
|
|
1,533 |
|
|
|
— |
|
|
|
— |
|
|
|
1,533 |
|
Issuance of common stock upon release of restricted stock units |
|
|
1,461,448 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net share settlements for stock-based minimum tax withholdings |
|
|
(14,036 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
25,915 |
|
|
|
— |
|
|
|
— |
|
|
|
25,915 |
|
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
624 |
|
|
|
— |
|
|
|
624 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(89,532 |
) |
|
|
(89,532 |
) |
Balance as of June 30, 2022 |
|
|
451,325,517 |
|
|
$ |
45 |
|
|
$ |
2,137,608 |
|
|
$ |
803 |
|
|
$ |
(1,284,260 |
) |
|
$ |
854,196 |
|
Issuance of common stock upon exercise of stock options |
|
|
1,430,629 |
|
|
|
— |
|
|
|
2,498 |
|
|
|
— |
|
|
|
— |
|
|
|
2,498 |
|
Issuance of common stock upon release of restricted stock units |
|
|
1,580,591 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net share settlements for stock-based minimum tax withholdings |
|
|
(14,038 |
) |
|
|
— |
|
|
|
(86 |
) |
|
|
— |
|
|
|
— |
|
|
|
(86 |
) |
Issuance of common stock under employee stock purchase plan |
|
|
1,130,337 |
|
|
|
— |
|
|
|
3,238 |
|
|
|
— |
|
|
|
— |
|
|
|
3,238 |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
24,710 |
|
|
|
— |
|
|
|
— |
|
|
|
24,710 |
|
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
829 |
|
|
|
— |
|
|
|
829 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(66,065 |
) |
|
|
(66,065 |
) |
Balance as of September 30, 2022 |
|
|
455,453,036 |
|
|
$ |
45 |
|
|
$ |
|